These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 21326075)

  • 1. Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia.
    Gallien S; Delaugerre C; Charreau I; Braun J; Boulet T; Barrail-Tran A; de Castro N; Molina JM; Kuritzkes DR
    AIDS; 2011 Mar; 25(5):665-9. PubMed ID: 21326075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.
    Scutari R; Alteri C; Vicenti I; Di Carlo D; Zuccaro V; Incardona F; Borghi V; Bezenchek A; Andreoni M; Antinori A; Perno CF; Cascio A; De Luca A; Zazzi M; Santoro MM;
    J Glob Antimicrob Resist; 2020 Mar; 20():163-169. PubMed ID: 31330378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.
    Cavaco-Silva J; Abecasis A; Miranda AC; Poças J; Narciso J; Águas MJ; Maltez F; Almeida I; Germano I; Diniz A; Gonçalves Mde F; Gomes P; Cunha C; Camacho RJ;
    PLoS One; 2014; 9(3):e92747. PubMed ID: 24681625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.
    da Silva D; Van Wesenbeeck L; Breilh D; Reigadas S; Anies G; Van Baelen K; Morlat P; Neau D; Dupon M; Wittkop L; Fleury H; Masquelier B
    J Antimicrob Chemother; 2010 Jun; 65(6):1262-9. PubMed ID: 20388636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.
    Modica S; Rossetti B; Lombardi F; Lagi F; Maffeo M; D'Autilia R; Pecorari M; Vicenti I; Bruzzone B; Magnani G; Paolucci S; Francisci D; Penco G; Sacchini D; Zazzi M; De Luca A; Di Biagio A
    HIV Med; 2019 Feb; 20(2):137-146. PubMed ID: 30461149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure.
    Fernández-Caballero JÁ; Chueca N; Álvarez M; Mérida MD; López J; Sánchez JA; Vinuesa D; Martínez MÁ; Hernández J; García F
    BMC Infect Dis; 2016 May; 16():197. PubMed ID: 27177767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.
    Ndashimye E; Avino M; Olabode AS; Poon AFY; Gibson RM; Li Y; Meadows A; Tan C; Reyes PS; Kityo CM; Kyeyune F; Nankya I; Quiñones-Mateu ME; Arts EJ
    J Antimicrob Chemother; 2020 Dec; 75(12):3525-3533. PubMed ID: 32853364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.
    Orta-Resendiz A; Rodriguez-Diaz RA; Angulo-Medina LA; Hernandez-Flores M; Soto-Ramirez LE
    AIDS Res Ther; 2020 Feb; 17(1):6. PubMed ID: 32041622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-Naive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1.
    Sayan M; Yildirim FS; Akhan S; Karaoglan I; Akalin H
    Curr HIV Res; 2022 Aug; 20(2):184-192. PubMed ID: 35240975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
    Ceccherini-Silberstein F; Van Baelen K; Armenia D; Trignetti M; Rondelez E; Fabeni L; Scopelliti F; Pollicita M; Van Wesenbeeck L; Van Eygen V; Dori L; Sarmati L; Aquaro S; Palamara G; Andreoni M; Stuyver LJ; Perno CF
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3938-48. PubMed ID: 20479206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants.
    Gutiérrez C; Hernández-Novoa B; Pérez-Elías MJ; Moreno AM; Holguín A; Dronda F; Casado JL; Moreno S
    HIV Clin Trials; 2013; 14(1):10-6. PubMed ID: 23372110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
    Cooper DA; Steigbigel RT; Gatell JM; Rockstroh JK; Katlama C; Yeni P; Lazzarin A; Clotet B; Kumar PN; Eron JE; Schechter M; Markowitz M; Loutfy MR; Lennox JL; Zhao J; Chen J; Ryan DM; Rhodes RR; Killar JA; Gilde LR; Strohmaier KM; Meibohm AR; Miller MD; Hazuda DJ; Nessly ML; DiNubile MJ; Isaacs RD; Teppler H; Nguyen BY;
    N Engl J Med; 2008 Jul; 359(4):355-65. PubMed ID: 18650513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of Integrase Strand Transfer Inhibitors (INSTI) Resistance Mutations in Taiwan.
    Chang SY; Lin PH; Cheng CL; Chen MY; Sun HY; Hsieh SM; Sheng WH; Su YC; Su LH; Chang SF; Liu WC; Hung CC; Chang SC
    Sci Rep; 2016 Oct; 6():35779. PubMed ID: 27779200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance.
    Hachiya A; Ode H; Matsuda M; Kito Y; Shigemi U; Matsuoka K; Imamura J; Yokomaku Y; Iwatani Y; Sugiura W
    Antiviral Res; 2015 Jul; 119():84-8. PubMed ID: 25956162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.
    Charpentier C; Karmochkine M; Laureillard D; Tisserand P; Bélec L; Weiss L; Si-Mohamed A; Piketty C
    HIV Med; 2008 Oct; 9(9):765-70. PubMed ID: 18651855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.
    Requena S; Treviño A; Cabezas T; Garcia-Delgado R; Amengual MJ; Lozano AB; Peñaranda M; Fernández JM; Soriano V; de Mendoza C;
    J Antimicrob Chemother; 2017 Jul; 72(7):2083-2088. PubMed ID: 28369593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.
    Malet I; Delelis O; Valantin MA; Montes B; Soulie C; Wirden M; Tchertanov L; Peytavin G; Reynes J; Mouscadet JF; Katlama C; Calvez V; Marcelin AG
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1351-8. PubMed ID: 18227187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary resistance to integrase strand-transfer inhibitors in Europe.
    Casadellà M; van Ham PM; Noguera-Julian M; van Kessel A; Pou C; Hofstra LM; Santos JR; Garcia F; Struck D; Alexiev I; Bakken Kran AM; Hoepelman AI; Kostrikis LG; Somogyi S; Liitsola K; Linka M; Nielsen C; Otelea D; Paraskevis D; Poljak M; Puchhammer-Stöckl E; Staneková D; Stanojevic M; Van Laethem K; Zidovec Lepej S; Clotet B; Boucher CA; Paredes R; Wensing AM;
    J Antimicrob Chemother; 2015 Oct; 70(10):2885-8. PubMed ID: 26188038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with the emergence of integrase resistance mutations in patients failing dual or triple integrase inhibitor-based regimens in a French national survey.
    Marcelin AG; Charpentier C; Bellecave P; Abdi B; Chaix ML; Ferre V; Raymond S; Fofana D; Bocket L; Mirand A; Le Guillou-Guillemette H; Montes B; Amiel C; Pallier C; Fafi-Kremer S; De Monte A; Alessandri-Gradt E; Scholtes C; Maillard A; Jeulin H; Bouvier-Alias M; Roussel C; Dos Santos G; Signori-Schmuck A; Dina J; Vallet S; Stefic K; Soulié C; Calvez V; Descamps D; Flandre P;
    J Antimicrob Chemother; 2021 Aug; 76(9):2400-2406. PubMed ID: 34100068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo.
    Delelis O; Thierry S; Subra F; Simon F; Malet I; Alloui C; Sayon S; Calvez V; Deprez E; Marcelin AG; Tchertanov L; Mouscadet JF
    Antimicrob Agents Chemother; 2010 Jan; 54(1):491-501. PubMed ID: 19901095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.